期刊文献+

肿瘤基因检测与分子靶向治疗 被引量:3

下载PDF
导出
摘要 近年来,随着肿瘤相关基础研究进展和一些技术方法的成熟和应用,如分子遗传、信号转导、生物信息学、蛋白质组学、基因组学、DNA重组、杂交瘤技术和生物芯片技术等,肿瘤分子靶向治疗进展迅速。自1997年11月美国食品药物管理局(FDA)批准利妥昔单抗用于非霍奇金淋巴瘤的靶向治疗以来,
出处 《检验医学与临床》 CAS 2012年第22期2871-2873,共3页 Laboratory Medicine and Clinic
  • 相关文献

参考文献3

二级参考文献22

  • 1吴辉塔,邓洁,于世英,王馨,陈元.The Inhibitory Effects of Rh-endostatin(YH-16) in Combination with Radiotherapy on Lung Adenocarcinoma A549 in Mice and the Underlying Mechanisms[J].Journal of Huazhong University of Science and Technology(Medical Sciences),2010,30(1):108-112. 被引量:10
  • 2王金万,孙燕,刘永煜,于起涛,张沂平,李凯,朱允中,周清华,侯梅,管忠震,李维廉,庄武,王东林,梁后杰,秦凤展,卢辉山,刘晓晴,孙红,张燕军,王杰军,罗素霞,杨瑞合,涂远荣,王秀问,宋恕平,周静敏,游丽芬,王竞,姚晨.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4):283-290. 被引量:625
  • 3王燕,孙燕.肿瘤靶向治疗现状和发展前景[J].中华肿瘤杂志,2005,27(10):638-640. 被引量:22
  • 4WANG Hui,YU Jin-ming,YANG Guo-ren,SONG Xian-rang,SUN Xiao-rong,ZHAO Shu-qiang,WANG Xing-wu,ZHAO Wei.Further characterization of the epidermal growth factor receptor ligand ^(11)C-PD153035[J].Chinese Medical Journal,2007(11):960-964. 被引量:10
  • 5[1]Shigematsu H,Lin L,Takahashi T,et al.Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.J Natl Cancer Inst,2005,97(5):339-346.
  • 6[2]Mok T,Lui P,Lam KC,et al.Novel mutations and mutation pattern of epidermal growth factor receptor (EGFR) gene in Chinese patients with primary lung adenocarcinoma (J/OL).J Clin Oncol,2007 ASCO Annual Meeting Proceedings,25(18S):7667[2007-07-01].http://meeting.ascopubs.org/cgi/content/short/25/18_suppl/7667.
  • 7[3]Holland W,Davies AM,Farneth NC,et al.Enhanced detection of EGFR mutations in plasma from non-small cell lung cancer (NSCLC)patients using Scorpion primers (J/OL).J Clin Oncol,2007 ASCO Annual Meeting Proceedings,25(18S):7682[2007-07-01].http://meeting.ascopubs.org/cgi/content/short/25/18_suppl/7682.
  • 8[4]Cohen V,Agulnik JS,Ang C,et al.Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR)gene mutations detected by denaturing high-performance liquid chromatography (dHPLC) in non-small cell lung cancer (NSCLC)(J/OL).J Clin Oncol,2007 ASCO Annual Meeting Proceedings,25(18S):7594[2007-07-01].http://meeting.ascopubs.org/cgi/content/short/25/18_ suppl/7594.
  • 9[5]Moran T,Paz-Ares L,Isla D,et al.High correspondence between EGFR mutations in tissue and in circulating DNA form non-small-cell lung cancer (NSCLC) patients (p) with poor performance status (PS)(J/OL).J Clin Oncol,2007 ASCO Annual Meeting Proceedings,25(18S):7505[2007-07-01].http://meeting.ascopubs.org/cgi/content/short/25/18_suppl/7505.
  • 10[6]Sequist LV,Martins RG,Spigel D,et al.iTARGET:A phase Ⅱ trial to assess the response to gefitinib in epidermal growth factor receptor(EGFR)-mutated non-small cell lung cancer (NSCLC) tumors (J/OL).J Clin Oncol,2007 ASCO Annual Meeting Proceedings,25(18S):7504[2007-07-01].http://meeting.ascopubs.org/cgi/content/short/25/18_suppl/7504.

共引文献9

同被引文献19

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部